source
- BMS CEO Boerner doesn’t ‘feel any compulsion to make deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.Fierce Biotech · 5h ago↗ source
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.Fierce Biotech · 6h ago↗ source
- Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.